Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia.

ABSTRACT:

Background

Bronchopulmonary dysplasia is a prevalent complication after extremely preterm birth. Inflammation with mechanical ventilation may contribute to its development. Whether hydrocortisone treatment after the second postnatal week can improve survival without bronchopulmonary dysplasia and without adverse neurodevelopmental effects is unknown.

Methods

We conducted a trial involving infants who had a gestational age of less than 30 weeks and who had been intubated for at least 7 days at 14 to 28 days. Infants were randomly assigned to receive either hydrocortisone (4 mg per kilogram of body weight per day tapered over a period of 10 days) or placebo. Mandatory extubation thresholds were specified. The primary efficacy outcome was survival without moderate or severe bro

SUBMITTER: Watterberg KL 

PROVIDER: S-EPMC9107291 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature